Você procurou por: concomitant use with (Inglês - Maltês)

concomitant use with
naqqas id-doża ta’

concomitant use with precautions
prekawzjonijiet għall-użu flimkien

concomitant use with valproic acid
użu flimkien ma’ valproic acid

concomitant use with opioid analgesics
użu flimkien ma’ analġeżiċi opioid

concomitant use with alpha-blockers
l-użu fl-istess ħin ma’ alpha-blockers

concomitant use with other pde5 inhibitors
l-użu fl-istess ħin ma’ inibituri oħrajn ta’ pde5

concomitant use with other medicinal products
l-użu flimkien ma’ prodotti mediċinali oħra

concomitant use with spironolactone (see section 4.5)
użu fl-istess ħin ma’ spironalactone (ara sezzjoni 4.5).

concomitant use with b cell targeted therapy or cyclophosphamide
l-użu flimkien ma’ terapija mmirata lejn iċ-ċelluli b jew cyclophosphamide

concomitant use with other vaccines has not been investigated.
l-użu flimkien ma’ vaċċini oħra ma ġiex investigat.

no data are available regarding concomitant use with other vaccines.
m’hemmx informazzjoni disponibbli dwar l-użu fl-istess ħin ma’ tilqim ieħor.

concomitant use with sultopride (see sections 4.5 and 5.1)
użu flimkien ma’ sultopride (ara sezzjonijiet 4.5 u 5.1)

no data are currently available regarding concomitant use with other vaccines.
fil- preżent m' hemm ebda informazzjoni disponibbli dwar l- użu konkomitanti ma 'tilqim ieħor.

concomitant use with ace inhibitors (see sections 4.4 and 4.5).
użu fl-istess ħin ma’ inibituri ta’ ace (ara sezzjonijiet 4.4 u 4.5).

concomitant use with medicinal products with a known potential to cause qtc prolongation
użu flimkien ma’ prodotti mediċinali magħrufa li jistgħu jikkawżaw titwil tal-qtc

concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity and ototoxicity.
l-użu fl-istess waqt ta' aminoglycosides jew cephalosporines jista' jżid ir-riskju ta' nefrotossiċità u ototossiċità.

the prescribing information for these levodopa preparations is applicable to their concomitant use with entacapone.
l- informazzjoni dwar kif jiġu ordnati dawn is-sustanzi ta’ levodopa hija applikabbli għall-użu tagħhom flimkien ma’ entacapone.

deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures.
rqad fil-fond u serħan mill-uġiġħ fil-klieb meta jintuża flimkien ma’ butorfanol għal proċeduri mediċi u proċeduri kirurġiċi żgħar.

lixiana 60 mg once daily is recommended during concomitant use with the following p-gp inhibitors:
lixiana 60 mg darba kuljum hu rakkomandat waqt l-użu fl-istess ħin mal-inibituri ta’ p-gp li ġejjin:

galafold is not intended for concomitant use with enzyme replacement therapy (see section 4.4).
galafold mhuwiex intiż għall-użu fl-istess ħinma’terapija ta' sostituzzjoni tal-enzima (ara sezzjoni 4.4).